Navigation Links
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Date:1/4/2008

m heart attacks annually in the U.S.(iii)

About prasugrel

Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) are co-developing prasugrel, an investigational oral antiplatelet agent invented by Daiichi Sankyo and its Japanese research partner Ube Industries, Ltd., as a potential treatment, initially for patients with acute coronary syndrome who are managed with PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke.

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product lineup and R&D pipeline.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first in class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

This press release contains certain f
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
3. Lilly Declares Fourth-Quarter Dividend
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
6. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Following the successful launch of On ... to introduce its new product and demonstrate its potential ... Launched in September, Formedix On Demand Services is the ... automation tools. For the first time, these market-leading tools ... introducing Formations – a revolutionary new token-based payment system ...
(Date:10/31/2014)... 31, 2014 The report "Dairy ... Formulation (Plain, Flavored, Sweetened, Unsweetened), Channel (Supermarket, Health ... Trends & Forecast to 2018," defines and segments ... and forecast of revenue and volume for plant-based ... projected to reach $14 Billion by 2018 with ...
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/31/2014)... 31, 2014  Tavistock Development Co. (TDC), a ... celebrated the groundbreaking of the GuideWell Innovation Center ... The 92,000-square-foot, three-story facility is the first ... designed specifically for life sciences, health innovation, ... the 650-acre Lake Nona Medical City, near the ...
Breaking Biology Technology:Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3
... silicon transistors in your computer may be replaced in ten ... scientists at the University of Gothenburg are hoping they ... Silicon is subject to certain limitations, and industry is ... sales of over USD 200 billion, and this means that ...
... Mass. , June 1 Merrimack Pharmaceuticals today announced that it will present ... Mulroy , President and Chief Executive Officer, will provide a company overview at 11:00am EDT ... , New York . , , , ... Merr i mack , ...
... LAKE CITY , June 1 Glycosan BioSystems ... gaining regulatory approval within the European Union for the use ... autologous adipose derived cells in reconstruction and aesthetic plastic surgery ... Mark as an implantable medical device.  HyStem-Rx will ...
Cached Biology Technology:Faster computers with nanotechnology 2Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference 2Glycosan BioSystems Seeks CE Mark in the European Union for HyStem-Rx, a Unique, Implantable Scaffold for Tissue Engineering 2
(Date:10/29/2014)... household and industrial products are in the environment – ... of them, scientists have yet to determine whether they ... toward doing that by estimating which substances people are ... in the ACS journal Environmental Science & Technology ... the risks to human health of any given substance ...
(Date:10/29/2014)... New York City on September 19, 2014, leading geneticist ... Professor of Genome Sciences and Medicine at the University ... Philosophy of Tel Aviv University, was awarded the 2014 ... addition to her honorary degree from TAU, Prof. King ... of Medicine, and for the past 18 years she ...
(Date:10/29/2014)... news release is available in German . ... like another: Gabriela Cabral and Peter Schlögelhofer at the ... Vienna and the Medical University of Vienna dived into ... revealed that these plants display an inversion of the ... in the scientific journal Nature Communications . , ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Meiotic cell division 'the other way round' 2
... new quarterly newsletter for academic librarians and information professionals. ... developments at OUP and across the publishing world. ... and member of the Editorial Team said: ,After careful ... developed a strong and broad source of information for ...
... has been largely overlooked by the public until now. ... of 157 scientists (the Nasonia Genome Working Group) ... University of Rochester, and Stephen Richards at the Genome Sequencing ... the genomes of three parasitoid wasp species. The genomes reveal ...
... 500,000 funding for the Peninsula Dental School to pursue three ... was announced today. The first area of research will ... published evidence and the creation of new approaches to understanding ... will look at the use of virtual reality and psychological ...
Cached Biology News:Genome advances peril for pests 2Genome advances peril for pests 3Genome advances peril for pests 4University of Plymouth invests in dental research 2
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... a positive selection for creating baculovirus recombinants ... insect cells. The kit improves on the ... eliminating the time-consuming steps of plaque purification. ... with a portion of the essential open ...
... General description: Dish uses include large-scale colony-counting ... with PBA Flexys TM automated colony ... is a new product number, created to ... no availability yet, please order under the ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Biology Products: